Alisertib is an investigational, oral, selective inhibitor of Aurora kinase A. In patients with refractory or recurrent SCLC, alisertib has been shown to be active both in monotherapy and in combination with paclitaxel [36,37]. The gene discussed is AURKA; the disease is small cell lung carcinoma.